logo
Challenges pharma companies face in push into US manufacturing

Challenges pharma companies face in push into US manufacturing

Yahooa day ago

Yahoo Finance senior health reporter Anjalee Khemlani explains the pharmaceutical industry's push into domestic manufacturing in the US, as a reshoring tactic to tighten up the supply chain. Planning can still take several years to be finalized and face cost barriers amid tariffs.
To watch more expert insights and analysis on the latest market action, check out more Market Domination here.
Well, the pharmaceutical industry has its eye on US-based manufacturing. What does that mean near term for the sector? Yahoo Finance's Anjali Comlani joins us now with more on obviously there's been a big push in many different industries to reshore manufacturing.
Um, pharmaceutical companies seem pretty much on board with this, but what does it look like in actuality?
Well, it actually is that they're on board and they have been, but not for the reasons that have anything to do with tariffs. This is not something new for them. Really, the pharma industry has been pushing for reshoring since the COVID-19 pandemic. And that's because that's when they first learned of the risk of the supply chain. So what we have now is this like grand big number, 270 billion plus in investment dollars that has been announced by some of the major companies in the last few months. And that is because of projects that have already been on the table or new projects that they may have pushed up the launch for announcement for in light of the Trump administration pressuring with tariffs and the threat of tariffs. The idea being that if they commit to these reshoring projects, then they will somehow get out of the tariffs. Now, that doesn't seem to be panning out. We know that the Trump administration has said that they will be announcing some sort of tariff soon. So all eyes on that, and what that means then for these companies, will they continue to commit? Will they slow down the pace of them? We're going to sit there and and and wait for them to tell us. But in the meantime, just take a look at the pros and cons of what this reshoring really looks like. On the pro side, you have a majority of drugs currently being produced in Europe and Asia. Europe takes the branded and Asia really for the generics. Now, US really uses a lot of generic drugs, so a lot of our reliance is on Asia for that reason. As I mentioned, COVID-19 showed us that the supply chain is at risk, and so bringing it back will help us with that. Also, newer medications, personalized medications, need to be closer to home. And that's one of the reasons why these companies were already focused on reshoring, or rather opening plants here, because there are some newer medications that have maybe shorter shelf lives or need to be closer to the patient. Um, it's just an easier process. Meanwhile, these companies are also looking at patent cliffs. And that's something that would help boost more manufacturing because they need to focus on their R&D pipeline, and that requires more manufacturing for dosing for clinical trials and the like. Now, looking at the disadvantages, uh, costs are up at this current time in part, thanks to tariffs on some of the construction material. Also, the construction area specifically for manufacturing for pharma, they are facing labor shortages and some of them is getting disrupted by immigration. So that's stressing the sector and means that any of these projects could hit snags and pauses. There's also the pressure from the inflation reduction Act and the most favored nations clauses, and how much price absorption the company is has to do, the companies will have to deal with there. Meanwhile, also, the planning takes about three to five years. So if they're looking at rolling out these plans by 2030, um, they should really be on it right about now to make that happen. I also want to talk about, um, some of the areas. One really interesting thing that is happening though with this shift and this focus is I want to take a look at this map right now, which has sort of these established hubs for pharma manufacturing. You know that the West Coast and California, um, as well as the East Coast, North Carolina, that research triangle, New York, New Jersey area, as well as Boston, has been major hub. Texas and Ohio are coming up interestingly enough, as well as a little bit of South Carolina tied to North Carolina, and then Indianapolis. That one's interesting to me because that is all and entirely Eli Lilly. Thanks to the JLP1. So we're seeing some more interest in some different areas. So what I'm interested in seeing is how much that really appeases the Trump administration, which wants to bring back, you know, manufacturing at large, and will it actually succeed in doing that for this industry? That's the question.
Yeah. All right. Thank you, Ange. Appreciate it.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Chinese Carmakers Agree to Standardize Supplier Payment Periods
Chinese Carmakers Agree to Standardize Supplier Payment Periods

Bloomberg

time32 minutes ago

  • Bloomberg

Chinese Carmakers Agree to Standardize Supplier Payment Periods

Several of China's state-owned automakers have pledged to standardize bill payment periods for their suppliers to 60 days after authorities raised concerns about supply chain financing. At least three carmakers, including Dongfeng Motor Group Co., Guangzhou Automobile Group Co. and China FAW Group Co. issued similar statements on Tuesday saying their payment plans are aimed at promoting efficient capital flows across supply chains in the automotive industry.

Buy LRCX Stock At $90?
Buy LRCX Stock At $90?

Forbes

time36 minutes ago

  • Forbes

Buy LRCX Stock At $90?

CANADA - 2025/02/10: In this photo illustration, the Lam Research Corporation logo is seen displayed ... More on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) Lam Research (NASDAQ:LRCX) stock has experienced a notable increase this year, rising by 22% and significantly outperforming the S&P 500's modest gain of 2%. This remarkable performance can be attributed primarily to the company's solid quarterly results, fueled by strong foundry revenues and improving margins. Given this recent surge, the crucial question for investors is whether LRCX is still a compelling purchase. We believe it is. Despite its current price hovering around $90, we see little reason for worry regarding LRCX stock, particularly in light of its reasonable valuation. Our conclusion stems from a thorough analysis of Lam Research's operational performance in recent years, along with its current and historical financial health. We have assessed the company based on several core metrics: Growth, Profitability, Financial Stability, and Downturn Resilience. Our results show that Lam Research demonstrates exceptionally strong operating performance and financial stability, positioning it as an attractive investment option. However, for those investors who prefer lower volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative — it has outperformed the S&P 500 and delivered returns exceeding 91% since its inception. Separately, see – What's Better – Circle Stock Or Bitcoin? When considering what you pay per dollar of sales or profit, LRCX stock appears slightly overvalued in relation to the wider market. Lam Research's Revenues have demonstrated significant growth over the past few years. Lam Research's profit margins are significantly higher than those of most companies in the Trefis coverage universe. Lam Research's balance sheet appears very robust. LRCX stock has underperformed compared to the benchmark S&P 500 index during some recent downturns. Concerned about how a market crash could affect LRCX stock? Our dashboard How Low Can Lam Research Stock Go In A Market Crash? provides an in-depth analysis of how the stock has fared during and after previous market crashes. In conclusion, Lam Research's performance across the discussed metrics is summarized as follows: Overall, Lam Research has demonstrated excellent performance across the critical metrics we evaluated. We believe this strong operational and financial health is not entirely reflected in the current moderate valuation of the stock, making LRCX an appealing investment. This further reinforces our belief that Lam Research is a solid investment choice. Although LRCX stock appears promising, investing in a single stock can entail risks. Conversely, the Trefis High Quality (HQ) Portfolio, comprising 30 stocks, has consistently outperformed the S&P 500 over the past 4-year period. Why is that the case? As a group, HQ Portfolio stocks yielded better returns with lower risk in comparison to the benchmark index; providing a smoother ride, as shown in HQ Portfolio performance metrics.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store